Mark R Bauter, Laura M Brutscher, Laurie C Dolan, Jessica L Spears
{"title":"BV379 株 BV379 芽孢杆菌对斯普拉格-道利大鼠的亚慢性口服毒性评估。","authors":"Mark R Bauter, Laura M Brutscher, Laurie C Dolan, Jessica L Spears","doi":"10.1177/09603271241278977","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The spore-forming bacterial species <i>Bacillus velezensis</i> is commonly utilized in feed for livestock and aquaculture. In recent years, there has been increased interest in introducing <i>B</i>. <i>velezensis</i> into human supplements and food. Before it can be safely administered in humans, the safety of each <i>B</i>. <i>velezensis</i> strain needs to be established. The objective of this study was to evaluate the in vivo safety of <i>Bacillus velezensis</i> strain BV379 by high-dose oral administration to rats in a 28-day subchronic toxicity study.</p><p><strong>Methods: </strong>In this study, 80 animals were assigned to four groups: vehicle control, 1 × 10<sup>10</sup>, 4 × 10<sup>10</sup>, or 10 × 10<sup>10</sup> CFU/kg bw/day by gavage. The following toxicological assessments were performed: ophthalmological examinations; observations for viability, signs of gross toxicity, and behavioral changes; in-life parameters, including body weight and food consumption; urinalysis, hematology, clinical chemistry, and coagulation assessments; macroscopic and microscopic tissue assessments; and bacterial enumeration in selected tissues.</p><p><strong>Results: </strong>Under the conditions of this study, no adverse clinical endpoints were attributed to the administration of <i>Bacillus velezensis</i> strain BV379, which was well-tolerated up to the highest dose of 10 × 10<sup>10</sup> CFU/kg bw/day.</p><p><strong>Conclusion: </strong>These results support the in vivo pre-clinical safety of <i>Bacillus velezensis</i> strain BV379 for use in food and supplements.</p>","PeriodicalId":94029,"journal":{"name":"Human & experimental toxicology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Subchronic oral toxicity assessment of <i>Bacillus velezensis</i> strain BV379 in sprague-dawley rats.\",\"authors\":\"Mark R Bauter, Laura M Brutscher, Laurie C Dolan, Jessica L Spears\",\"doi\":\"10.1177/09603271241278977\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The spore-forming bacterial species <i>Bacillus velezensis</i> is commonly utilized in feed for livestock and aquaculture. In recent years, there has been increased interest in introducing <i>B</i>. <i>velezensis</i> into human supplements and food. Before it can be safely administered in humans, the safety of each <i>B</i>. <i>velezensis</i> strain needs to be established. The objective of this study was to evaluate the in vivo safety of <i>Bacillus velezensis</i> strain BV379 by high-dose oral administration to rats in a 28-day subchronic toxicity study.</p><p><strong>Methods: </strong>In this study, 80 animals were assigned to four groups: vehicle control, 1 × 10<sup>10</sup>, 4 × 10<sup>10</sup>, or 10 × 10<sup>10</sup> CFU/kg bw/day by gavage. The following toxicological assessments were performed: ophthalmological examinations; observations for viability, signs of gross toxicity, and behavioral changes; in-life parameters, including body weight and food consumption; urinalysis, hematology, clinical chemistry, and coagulation assessments; macroscopic and microscopic tissue assessments; and bacterial enumeration in selected tissues.</p><p><strong>Results: </strong>Under the conditions of this study, no adverse clinical endpoints were attributed to the administration of <i>Bacillus velezensis</i> strain BV379, which was well-tolerated up to the highest dose of 10 × 10<sup>10</sup> CFU/kg bw/day.</p><p><strong>Conclusion: </strong>These results support the in vivo pre-clinical safety of <i>Bacillus velezensis</i> strain BV379 for use in food and supplements.</p>\",\"PeriodicalId\":94029,\"journal\":{\"name\":\"Human & experimental toxicology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human & experimental toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/09603271241278977\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human & experimental toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/09603271241278977","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
导言:芽孢杆菌(Bacillus velezensis)通常用于家畜和水产养殖的饲料中。近年来,人们对将 B. velezensis 引入人类补充剂和食品的兴趣日益浓厚。在对人类安全施用之前,需要确定每种 B. velezensis 菌株的安全性。本研究的目的是通过对大鼠进行为期 28 天的亚慢性毒性研究,评估高剂量口服 Velezensis 杆菌菌株 BV379 在体内的安全性:在这项研究中,80只大鼠被分为四组:给药对照组、1×1010、4×1010或10×1010 CFU/kg体重/天组。进行了以下毒理学评估:眼科检查;观察存活率、大体毒性迹象和行为变化;生活参数,包括体重和食物消耗量;尿液分析、血液学、临床化学和凝血评估;宏观和微观组织评估;以及选定组织中的细菌计数:结果:在本研究的条件下,施用韦氏芽孢杆菌菌株 BV379 未导致任何不良临床终点:这些结果证明了在食品和补充剂中使用韦氏芽孢杆菌菌株 BV379 的体内临床前安全性。
Subchronic oral toxicity assessment of Bacillus velezensis strain BV379 in sprague-dawley rats.
Introduction: The spore-forming bacterial species Bacillus velezensis is commonly utilized in feed for livestock and aquaculture. In recent years, there has been increased interest in introducing B. velezensis into human supplements and food. Before it can be safely administered in humans, the safety of each B. velezensis strain needs to be established. The objective of this study was to evaluate the in vivo safety of Bacillus velezensis strain BV379 by high-dose oral administration to rats in a 28-day subchronic toxicity study.
Methods: In this study, 80 animals were assigned to four groups: vehicle control, 1 × 1010, 4 × 1010, or 10 × 1010 CFU/kg bw/day by gavage. The following toxicological assessments were performed: ophthalmological examinations; observations for viability, signs of gross toxicity, and behavioral changes; in-life parameters, including body weight and food consumption; urinalysis, hematology, clinical chemistry, and coagulation assessments; macroscopic and microscopic tissue assessments; and bacterial enumeration in selected tissues.
Results: Under the conditions of this study, no adverse clinical endpoints were attributed to the administration of Bacillus velezensis strain BV379, which was well-tolerated up to the highest dose of 10 × 1010 CFU/kg bw/day.
Conclusion: These results support the in vivo pre-clinical safety of Bacillus velezensis strain BV379 for use in food and supplements.